[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642174":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":16,"studyPopulation":37,"armGroups":38,"interventions":16,"overallOfficials":16,"centralContacts":41,"locations":16,"responsibleParty":47,"collaborators":16,"id":50,"slug":16,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":16,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":16,"enrollmentInfo":58,"targetDuration":16,"studyType":61,"phases":16,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":16,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":16},{"fullName":5,"class":6},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in percentage of peripheral blood CD8+ CD57+ T cells measured by CyTOF","CyTOF mass cytometry will measure percentages of CD4+ T cells, CD8+ T cells, B cells, NK cells, Naive\u002FTCM\u002FTEM\u002FTEMRA subsets, CD57-positive cells, HLA-DR\u002FCD38-positive cells, and PD-1\u002FCTLA-4\u002FTIM-3\u002FTIGIT-positive cells. The outcome is the change from baseline in each prespecified percentage or marker-positive frequency.","Baseline and routine follow-up blood collections through 24 months",[14,18,21,23,26,28,30,32],{"measure":15,"description":16,"timeFrame":17},"Number and percentage of participants with pulmonary nodule evolution events assessed by routine chest CT",null,"Baseline through 24 months",{"measure":19,"description":16,"timeFrame":20},"CMV IgG serostatus measured by institutional immunoassay","Baseline",{"measure":22,"description":16,"timeFrame":17},"Research blood collection completion rate",{"measure":24,"description":16,"timeFrame":25},"Blood draw-related adverse events","At each research blood collection visit from baseline through 24 months",{"measure":27,"description":16,"timeFrame":20},"EBV VCA-IgG serostatus measured by institutional immunoassay",{"measure":29,"description":16,"timeFrame":20},"EBV EBNA-IgG serostatus measured by institutional immunoassay",{"measure":31,"description":16,"timeFrame":20},"HPV L1 antibody serostatus measured by institutional immunoassay",{"measure":33,"description":16,"timeFrame":17},"CyTOF assay completion rate",{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":35,"timePerspective":36,"maskingInfo":16},"COHORT","RETROSPECTIVE","Adults who have undergone surgical resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up at participating centers. Participants will be identified from thoracic surgery clinics, inpatient services, and routine postoperative follow-up programs. Eligible participants will provide written informed consent and will be followed according to usual clinical care; research blood samples and study data will be collected at clinically scheduled visits when routine blood draws and follow-up data are available.",[39],{"label":40,"type":16,"description":16,"interventionNames":16},"Postoperative Multiple Pulmonary Nodule Cohort",[42],{"name":43,"role":44,"phone":45,"phoneExt":16,"email":46},"Jianxing He","CONTACT","020-83062810","jianxinghe@gzhmu.edu.cn",{"type":48,"investigatorFullName":43,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100642174",false,"NCT07647055","Single-Center CyTOF and Viral Imprinting Study in Postoperative Multiple Pulmonary Nodules","A Single-Center Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\n* Age 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\n* Investigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.","ALL","18 Years",{"count":59,"type":60},200,"ESTIMATED","OBSERVATIONAL","This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T\u002FB\u002FNK cell phenotypes, T-cell differentiation and senescence\u002Fexhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.",[64],"Multiple Pulmonary Nodules",[66],"CyTOF","NOT_YET_RECRUITING","2026-06-09",{"date":70,"type":71},"2026-06-15","ACTUAL",{"date":73,"type":60},"2026-07",{"date":75,"type":60},"2028-12",{"name":5,"class":6}]